Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial

AIM: To compare the efficacy and safety of a simple daily titration algorithm compared with a weekly dose adjustment of iGlarLixi in people with type 2 diabetes. MATERIALS AND METHODS: LixiLan ONE CAN (NCT03767543), a randomized, 26‐week, open‐label, multicentre phase 3 trial conducted in Canada, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hramiak, Irene, Gerstein, Hertzel C., Leiter, Lawrence A., Yale, Jean‐François, Bajaj, Harpreet S., Stewart, John, Toutounji, Marie‐Josée, Harris, Stewart B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546064/
https://www.ncbi.nlm.nih.gov/pubmed/35670659
http://dx.doi.org/10.1111/dom.14787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546064/
https://www.ncbi.nlm.nih.gov/pubmed/35670659
http://dx.doi.org/10.1111/dom.14787

Ejemplares similares